Repligen (NASDAQ:RGEN) Downgraded by Wall Street Zen to Hold

Wall Street Zen downgraded shares of Repligen (NASDAQ:RGEN) from a buy rating to a hold rating in a research note published on Saturday.

Several other equities research analysts have also commented on RGEN. UBS Group reduced their price target on shares of Repligen from $200.00 to $195.00 and set a “buy” rating for the company in a report on Wednesday. Barclays cut their price objective on shares of Repligen from $200.00 to $175.00 and set an “overweight” rating on the stock in a report on Wednesday. Wells Fargo & Company lowered their target price on Repligen from $190.00 to $180.00 and set an “overweight” rating for the company in a report on Wednesday. KeyCorp reiterated an “overweight” rating on shares of Repligen in a report on Wednesday. Finally, Weiss Ratings raised Repligen from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Tuesday, February 17th. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $174.58.

Repligen Trading Down 3.7%

Shares of NASDAQ RGEN opened at $128.73 on Friday. Repligen has a twelve month low of $102.96 and a twelve month high of $175.77. The firm has a market cap of $7.25 billion, a PE ratio of 151.45, a price-to-earnings-growth ratio of 2.44 and a beta of 1.13. The business has a fifty day simple moving average of $154.18 and a two-hundred day simple moving average of $146.97. The company has a quick ratio of 7.14, a current ratio of 8.37 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings results on Tuesday, February 24th. The biotechnology company reported $0.49 EPS for the quarter, beating the consensus estimate of $0.44 by $0.05. The firm had revenue of $197.91 million for the quarter, compared to analyst estimates of $192.23 million. Repligen had a return on equity of 4.71% and a net margin of 6.62%.The business’s revenue for the quarter was up 18.1% on a year-over-year basis. During the same quarter last year, the firm posted $0.44 earnings per share. Repligen has set its FY 2026 guidance at 1.930-2.010 EPS. Analysts expect that Repligen will post 1.72 earnings per share for the current fiscal year.

Insider Buying and Selling at Repligen

In related news, Director Karen A. Dawes sold 275 shares of the company’s stock in a transaction dated Wednesday, December 17th. The stock was sold at an average price of $161.00, for a total transaction of $44,275.00. Following the transaction, the director directly owned 91,821 shares of the company’s stock, valued at $14,783,181. This represents a 0.30% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. 1.20% of the stock is owned by insiders.

Institutional Investors Weigh In On Repligen

A number of large investors have recently modified their holdings of RGEN. Wealth Enhancement Advisory Services LLC raised its position in shares of Repligen by 1.9% in the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 4,001 shares of the biotechnology company’s stock valued at $584,000 after purchasing an additional 75 shares during the last quarter. NewEdge Wealth LLC increased its stake in Repligen by 5.3% during the 4th quarter. NewEdge Wealth LLC now owns 1,492 shares of the biotechnology company’s stock valued at $244,000 after purchasing an additional 75 shares in the last quarter. UMB Bank n.a. raised its holdings in shares of Repligen by 13.8% in the fourth quarter. UMB Bank n.a. now owns 758 shares of the biotechnology company’s stock worth $124,000 after buying an additional 92 shares during the last quarter. Hilltop National Bank lifted its stake in shares of Repligen by 8.0% during the third quarter. Hilltop National Bank now owns 1,276 shares of the biotechnology company’s stock worth $171,000 after buying an additional 95 shares during the period. Finally, ProShare Advisors LLC lifted its stake in shares of Repligen by 4.3% during the second quarter. ProShare Advisors LLC now owns 2,316 shares of the biotechnology company’s stock worth $288,000 after buying an additional 96 shares during the period. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.